Figure 2 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Figure 2 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

<p>5hmC patterns change at different states and subgroups of prostate cancer. <b>A,</b> Unsupervised visualization of global 5hmC patterns for different prostate cancer states using principal component analysis for gene body counts of the top 10% variable protein coding genes. Beni...

Volledige beschrijving

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Martin Sjöström (14845882) (author)
Andere auteurs:	Shuang G. Zhao (12227671) (author), Samuel Levy (14960811) (author), Meng Zhang (14960814) (author), Yuhong Ning (279537) (author), Raunak Shrestha (14949693) (author), Arian Lundberg (14960817) (author), Cameron Herberts (14960820) (author), Adam Foye (14960823) (author), Rahul Aggarwal (14960826) (author), Junjie T. Hua (14960829) (author), Haolong Li (1532230) (author), Anna Bergamaschi (14960832) (author), Corinne Maurice-Dror (14960835) (author), Ashutosh Maheshwari (14960838) (author), Sujun Chen (3553841) (author), Sarah W.S. Ng (14960841) (author), Wenbin Ye (14960844) (author), Jessica Petricca (14960847) (author), Michael Fraser (522709) (author), Lisa Chesner (14960850) (author), Marc D. Perry (14960853) (author), Thaidy Moreno-Rodriguez (14960856) (author), William S. Chen (14960859) (author), Joshi J. Alumkal (14950518) (author), Jonathan Chou (14957015) (author), Alicia K. Morgans (5600567) (author), Tomasz M. Beer (14960862) (author), George V. Thomas (13187926) (author), Martin Gleave (146446) (author), Paul Lloyd (14960865) (author), Tierney Phillips (4664332) (author), Erin McCarthy (14960868) (author), Michael C. Haffner (14960871) (author), Amina Zoubeidi (14960874) (author), Matti Annala (219688) (author), Robert E. Reiter (14960877) (author), Matthew B. Rettig (14960880) (author), Owen N. Witte (14960883) (author), Lawrence Fong (14960886) (author), Rohit Bose (14960889) (author), Franklin W. Huang (10726678) (author), Jianhua Luo (14960892) (author), Anders Bjartell (199682) (author), Joshua M. Lang (12227674) (author), Nupam P. Mahajan (14960895) (author), Primo N. Lara (13009812) (author), Christopher P. Evans (14960898) (author), Phuoc T. Tran (14960901) (author), Edwin M. Posadas (14960904) (author), Chuan He (178952) (author), Xiao-Long Cui (2020402) (author), Jiaoti Huang (88989) (author), Wilbert Zwart (14960907) (author), Luke A. Gilbert (5513207) (author), Christopher A. Maher (14960910) (author), Paul C. Boutros (14954698) (author), Kim N. Chi (14960913) (author), Alan Ashworth (14957030) (author), Eric J. Small (14960916) (author), Housheng H. He (14960919) (author), Alexander W. Wyatt (14960922) (author), David A. Quigley (14957012) (author), Felix Y. Feng (14845891) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Cancer Risk Factors Molecular and Cellular Biology Methods and Technology Epigenetics Epigenomics Genitourinary Cancers Prostate cancer Liquid Biopsy
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Figure 5 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
door: Martin Sjöström (14845882)
Gepubliceerd in: (2025)

Figure 1 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
door: Martin Sjöström (14845882)
Gepubliceerd in: (2025)

Figure 3 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
door: Martin Sjöström (14845882)
Gepubliceerd in: (2025)

Figure 4 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
door: Martin Sjöström (14845882)
Gepubliceerd in: (2025)

Figure 6 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
door: Martin Sjöström (14845882)
Gepubliceerd in: (2025)

Figure 7 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
door: Martin Sjöström (14845882)
Gepubliceerd in: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
door: Martin Sjöström (14845882)
Gepubliceerd in: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
door: Martin Sjöström (14845882)
Gepubliceerd in: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
door: Martin Sjöström (14845882)
Gepubliceerd in: (2025)

Supplementary Figure 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
door: Alex Chehrazi-Raffle (17079582)
Gepubliceerd in: (2025)

Supplementary Data 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
door: Alex Chehrazi-Raffle (17079582)
Gepubliceerd in: (2025)

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
door: Sofie H. Tolmeijer (15313251)
Gepubliceerd in: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
door: Sofie H. Tolmeijer (15313251)
Gepubliceerd in: (2025)

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
door: Sofie H. Tolmeijer (15313251)
Gepubliceerd in: (2025)

Supplementary Data from DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations
door: John Gallon (15096459)
Gepubliceerd in: (2025)

Supplementary Data 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
door: Arian Lundberg (14960817)
Gepubliceerd in: (2025)

Supplementary Data 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
door: Arian Lundberg (14960817)
Gepubliceerd in: (2025)

Supplementary Table 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
door: Arian Lundberg (14960817)
Gepubliceerd in: (2025)

Supplementary Table 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
door: Arian Lundberg (14960817)
Gepubliceerd in: (2025)

Supplementary Table 3. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
door: Arian Lundberg (14960817)
Gepubliceerd in: (2025)

Supplementary Data 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
door: Hong Qiu (14963144)
Gepubliceerd in: (2025)

Supplementary Data 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
door: Hong Qiu (14963144)
Gepubliceerd in: (2025)

Supplementary Table S1 from G-Quadruplex Structures Are Key Modulators of Somatic Structural Variants in Cancers
door: Rongxin Zhang (15293341)
Gepubliceerd in: (2025)

Supplementary Table S2 from G-Quadruplex Structures Are Key Modulators of Somatic Structural Variants in Cancers
door: Rongxin Zhang (15293341)
Gepubliceerd in: (2025)

Supplementary Table S5 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
door: Abdullah A. Osman (15056323)
Gepubliceerd in: (2025)

Supplementary Figure S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
door: Abdullah A. Osman (15056323)
Gepubliceerd in: (2025)

Supplementary Table S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
door: Abdullah A. Osman (15056323)
Gepubliceerd in: (2025)

Supplementary Table S2 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
door: Abdullah A. Osman (15056323)
Gepubliceerd in: (2025)

Supplementary Table S3 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
door: Abdullah A. Osman (15056323)
Gepubliceerd in: (2025)

Supplementary Table S4 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
door: Abdullah A. Osman (15056323)
Gepubliceerd in: (2025)

Supplementary Tables 1 from Proteostasis Modulation in Germline Missense von Hippel Lindau Disease
door: Prashant Chittiboina (15367044)
Gepubliceerd in: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
door: Emil Christensen (15054394)
Gepubliceerd in: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
door: Emil Christensen (15054394)
Gepubliceerd in: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
door: James R. Larkin (14936324)
Gepubliceerd in: (2025)

Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
door: Stephanie Lheureux (16797697)
Gepubliceerd in: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
door: Kala Visvanathan (14952973)
Gepubliceerd in: (2025)

Supplementary Data from β-Catenin–Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer
door: Dipika R. Mohan (15011204)
Gepubliceerd in: (2025)

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
door: Stephanie Lheureux (16797697)
Gepubliceerd in: (2025)

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
door: Stephanie Lheureux (16797697)
Gepubliceerd in: (2025)

Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
door: Stephanie Lheureux (16797697)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_v9kcjipvc9d2rrqosf89ilr6a7